F-1/A: IceCure Medical Launches $10 Million Rights Offering Amidst FDA Review and Geopolitical Tensions

IceCure Medical Ltd. has filed an amended F-1 registration statement for a non-transferable rights offering aiming to raise up to $10 million to fund operations and repay a bridge loan, while navigating a delayed FDA marketing authorization for its ProSense system and regional geopolitical risks.

Summary

• IceCure Medical Ltd. is conducting a non-transferable rights offering to raise up to $10,000,000 in gross proceeds.
• The offering involves up to 10,000,000 Units, priced at $1.00 per Unit, each consisting of one Ordinary Share and one Warrant to purchase an Ordinary Share at an exercise price of $1.00.
• Alternatively, investors whose beneficial ownership would exceed 4.99% (or 9.99% by election) can purchase Pre-Funded Warrants (exercise price $0.0001) instead of Ordinary Shares, reducing the Unit price to $0.9999.
• Shareholders receive one Subscription Right for every Ordinary Share owned as of the record date (July 9, 2025), with each right entitling the holder to purchase 0.1703 of a Unit, requiring at least six rights for one whole Unit.
• Epoch Partner Investments Limited, currently owning approximately 44.04% of outstanding Ordinary Shares, has committed to participate fully in its Basic Subscription Rights and purchase up to an additional $5,000,000 in unsubscribed Units via a Standby Commitment.
• The net proceeds from the offering, estimated at approximately $9.3 million (assuming full subscription), will be used to repay a $2,000,000 bridge loan from Epoch and for general corporate and working capital purposes.
• The Subscription Period is from July 10, 2025, to July 28, 2025, at 5:00 p.m. Eastern Time, and all exercises are irrevocable.
• The company's Ordinary Shares are listed on Nasdaq under the symbol ICCM, with a closing price of $1.00 per share on June 20, 2025.
• There is no established public trading market for the Pre-Funded Warrants or Warrants, and the company does not intend to list them.

Sentiment

Score: 4

Explanation: The capital raise is crucial for the company's operational continuity and commercialization efforts, and the standby commitment provides some financial stability. However, the significant dilution for new investors (78% in net tangible book value), the ongoing need for future capital, the non-transferability of rights, and the illiquidity of the warrants, coupled with the FDA's request for a post-market study delaying full marketing authorization, present considerable challenges and risks. The geopolitical risks in Israel also add a layer of uncertainty.

Positives

• The rights offering aims to secure up to $10 million in gross proceeds, addressing the company's immediate capital needs for operations and commercialization.
• Epoch Partner Investments Limited, a significant shareholder, has provided a standby commitment of up to $5 million, ensuring a minimum capital raise and demonstrating continued support.
• Proceeds will be used to repay a $2 million bridge loan, improving the company's short-term debt position.
• The company's lead product, ProSense, received a favorable advisory panel vote from the FDA for early-stage low-risk breast cancer, indicating progress towards potential marketing authorization.

Negatives

• The offering will result in significant immediate dilution for investors subscribing to Units, with a dilution of $0.78 per Ordinary Share, representing a 78% dilution in net tangible book value per share.
• Shareholders holding less than six Ordinary Shares on the record date will not be able to participate in the Rights Offering, limiting their ability to avoid dilution.
• The Subscription Rights are non-transferable, preventing shareholders from selling them to realize value.
• There will be no public trading market for the Pre-Funded Warrants or Warrants, limiting their liquidity for holders.
• The company will require additional capital beyond this offering to fund operations through May 31, 2026, and for commercialization efforts, indicating ongoing financing needs.
• Epoch's ownership could increase to 48.43% if other shareholders do not participate, potentially increasing its control over the company and matters requiring shareholder approval.

Risks

• Even if the Rights Offering is completed, the company will require additional capital to fund operations through May 31, 2026, and for commercialization efforts, with no assurance of obtaining it on acceptable terms.
• Investors will experience immediate and substantial dilution (78% in net tangible book value per share) due to the Subscription Price being higher than the as-adjusted net tangible book value; future equity offerings could cause further dilution.
• The market price of Ordinary Shares may be highly volatile and fluctuate substantially, potentially decreasing during or after the Rights Offering, leading to losses for investors.
• Subscription Rights are non-transferable, and there will be no public trading market for the Pre-Funded Warrants and Warrants, limiting liquidity and the ability to realize value.
• Epoch's increased ownership (potentially up to 48.43%) could give it significant control over shareholder matters, potentially delaying or preventing changes in control or management.
• Political, economic, and military instability in Israel, including ongoing multi-front conflicts, could adversely affect business operations, supply chains, and employee availability due to military service.
• Enforcing U.S. judgments against the company, its directors, and management may be difficult, particularly for those residing outside the United States (Israel, China, Hong Kong).
• The FDA has requested a post-market study for ProSense, which is expected to include a minimum of 400 patients at 25 sites, delaying the final marketing authorization decision.
• All exercises of Subscription Rights are irrevocable, even if unfavorable information about the company or its business emerges after the decision is made.
• Shareholders holding fewer than six Ordinary Shares on the Record Date will not be able to participate in the Rights Offering, limiting their ability to avoid dilution.

Future Outlook

The company intends to use the net proceeds from this Rights Offering, along with existing cash, to repay a bridge loan and for general corporate and working capital purposes. This includes establishing and expanding sales, marketing, and distribution infrastructure for the ProSense system, contingent on obtaining financing on favorable terms. The FDA has requested a post-market study for ProSense, expected to involve a minimum of 400 patients at 25 sites, with the final marketing authorization decision anticipated after the study plan's approval. The company believes current funds and offering proceeds will cover operating expenses and capital expenditures through May 31, 2026, but acknowledges the need for further funding thereafter.

Management Comments

• "We believe that our existing cash, cash equivalents and short-term investments, together with the net proceeds of approximately $9.3 million from this Rights Offering, assuming that the Rights Offering is consummated and fully subscribed, will enable us to fund our operating expenses and capital expenditure requirements through May 31, 2026."
• "Our management will have broad discretion in the allocation of the net proceeds and could use them for purposes other than those contemplated at the time of this Rights Offering and as described in the section titled Use of Proceeds."
• "None of our board of directors, the Subscription Agent or the Information Agent is making any recommendation regarding your exercise of Subscription Rights in the Rights Offering or the sale or transfer of the Ordinary Shares, the Pre-Funded Warrants and the Warrants or Ordinary Shares issuable upon exercise of the Pre-Funded Warrants and the Warrants. Further, we have not authorized anyone to make any recommendation."

Industry Context

This announcement highlights a critical phase for IceCure Medical, a medical device company, as it seeks to raise capital to support the commercialization of its cryoablation technology, ProSense. The need for a rights offering, coupled with the FDA's request for a post-market study for breast cancer indication, underscores the significant capital requirements and regulatory hurdles common in the medical device industry, particularly for companies transitioning from clinical trials to market entry. The offering aims to secure funding necessary to build out sales and marketing infrastructure, a typical step for medical device companies post-approval.

Corporate Governance

Related Party Transactions

• Epoch Partner Investments Limited, a related party (beneficially owns approximately 44.04% of outstanding Ordinary Shares), provided a $2,000,000 unsecured bridge loan to the company on May 17, 2025.
• Epoch has committed to participate in the Rights Offering by exercising its Basic Subscription Rights in full and Over-Subscription Privileges to purchase up to $5,000,000 in unsubscribed Units.
• The bridge loan agreement stipulates that if the company raises capital in an equity transaction (other than its at-the-market offering facility or any other equity line), the amount raised (up to the loan amount) shall be used for prepayment, subject to Epoch's participation in such capital raising.
• Epoch will not receive any fee for providing the Standby Commitment.
• Mr. Li Haixiang, a member of the company's board of directors, has the voting and dispositive power over the Ordinary Shares held by Epoch.

Stakeholder Impact

• **Shareholders**: Will experience significant immediate dilution (78% in net tangible book value) if they subscribe to Units. Existing shareholders who do not fully exercise their rights will see a decrease in their percentage ownership. Shareholders holding less than six Ordinary Shares cannot participate in the offering. There is a potential for increased control by Epoch if other shareholders do not fully participate.
• **Employees**: Operations may be disrupted by Israeli military reservist call-ups, as 10 employees were called up as of June 23, 2025, though most have since returned.
• **Creditors**: The repayment of the $2 million bridge loan to Epoch will improve the company's short-term debt position.

Next Steps

• Conduct a post-market study for ProSense (minimum 400 patients at 25 sites) as requested by the FDA.
• Present the post-market study plan to the CDRH for approval.
• Await FDA's final marketing authorization decision for ProSense for early-stage low-risk breast cancer.
• Repay the Bridge Loan amount to Epoch.
• Establish and expand sales, marketing, and distribution infrastructure for the ProSense system.
• Seek further funding beyond May 31, 2026.

Key Dates

Recommendation

Keywords

Cryoablation, Medical Device, ProSense, Rights Offering, SEC Filing, F-1/A, Capital Raise, Warrants, Pre-Funded Warrants, Dilution, Israel, FDA, Breast Cancer Treatment, Epoch Partner Investments, Nasdaq